NCT00134069View on ClinicalTrials.gov

Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

September 30, 2010

Study Completion Date

December 31, 2011

Conditions

Recurrent Colon CancerRecurrent Rectal CancerStage III Colon CancerStage III Rectal CancerStage IV Colon CancerStage IV Rectal Cancer

Interventions

DRUG

sorafenib tosylate

Given orally

DRUG

cetuximab

Given IV

DRUG

irinotecan hydrochloride

Given IV

Trial Locations (2)

80045

University of Colorado at Denver Health Sciences Center, Aurora

21287-8936

Johns Hopkins University, Baltimore

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00134069 - Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter